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Edited by Veli-Pekka LehtoAbstract The up-regulation of HER2/neu is associated with
human malignancies and is a useful target for developing anti-
cancer drugs. Overexpression of human manganese superoxide
dismutase (MnSOD) has been demonstrated to eﬀectively sup-
press various carcinoma cells, including breast carcinomas,
in vitro and in vivo. This study demonstrates that MnSOD eﬀec-
tively suppresses HER2/neu oncogene expression at the tran-
scriptional level. Additionally, stable transfection was used and
the MnSOD-transfected human breast cancer clones were found
to be able to down-regulate the endogenous production of
p185HER2/neu. Furthermore, the MnSOD-overexpressing stable
transfectants exhibited reduced soft-agarose colony-forming
ability and metastatic properties, unlike control cell lines. These
data suggest that MnSOD may be useful in treating HER2/neu-
mediated human breast tumor malignancy.
 2007 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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HER2/neu proto-oncogene (also known as c-erbB-2) was
ﬁrst cloned and veriﬁed from the rat neuro/glioblastomas that
were induced by ethylnitrosourea [1,2]. Located on chromo-Abbreviations: MnSOD, manganese superoxide dismutase; EGFR,
epidermal growth factor receptor; SOD, superoxide dismutase; CMV,
cytomegalovirus; PBS, phosphate-buﬀered saline; DMEM, Dulbecco’s
modiﬁed Eagle’s medium; FBS, fetal bovine serum; PAGE, polyacryl-
amide gel electrophoresis; NBT, nitroblue tetrazolium; TEMED,
N,N,N 0,N0-tetramethylethylenediamine; RNAi, RNA interference
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doi:10.1016/j.febslet.2007.08.021some 17q12-21, HER2/neu proto-oncogene encodes a receptor
tyrosine kinase protein with a molecular weight of 185 kDa
(p185HER2/neu) [3–5]. This gene is the second member of the
epidermal growth factor receptor (EGFR) family. A previous
study has demonstrated that the physiological function of
the HER2/neu gene is related to the neural and cardiac devel-
opment from gene knockout experiments in mice [6]. Since it
has no speciﬁc ligands, HER2/neu typically heterodimerizes
with other members of the EGFR family [4,5]. Extensive stud-
ies have shown that the ampliﬁcation and/or over-expression
of the HER2/neu proto-oncogene are associated with a wide
range of human cancers (about 30% in breast carcinoma).
The aberrant up-regulation of HER2/neu is associated with
the poor survival of cancer patients, and is considered to be
critical in tumorigenesis. Many works have suggested that
HER2/neu overexpression is also related to cytotoxic drug
resistance in patients and cell lines (reviewed in [4,5]). Hence,
the down-regulation of the HER2/neu oncogene expression
may be eﬀective in the treatment of HER2/neu-overexpressing
human cancers.
Reactive oxygen species (ROS) are generated endogenously
by all aerobic cells by the metabolism of oxygen. They are
involved in the regulation of various physiological reactions,
including signal transduction, apoptosis, diﬀerentiation and
senescence [7,8]. Oxidative damage by endogenous ROS not
only has been associated with the etiology of various patholog-
ical states but also participates in carcinogenesis. Superoxide
dismutase (SOD), catalase and peroxidase are three major pri-
mary intracellular antioxidant enzymes in mammalian cells.
All intracellular antioxidant enzymes in eukaryotic cells are
important in protecting cells from the damage by ROS. The
SODs and other antioxidant enzymes may also be pivotal in
carcinogenesis and drug resistance against malignant cells.
Moreover, low expression of antioxidant enzymes has been
observed in numerous solid tumors [9,10].
Manganese superoxide dismutase (MnSOD) is one of three
mammalian SODs. It is a primary antioxidant enzyme and is
localized in the matrix of mitochondria. MnSOD is known to
suppress cell growth in several tumor cells in vivo and in vitro
[10–13]. However, the molecular mechanism of this repressionblished by Elsevier B.V. All rights reserved.
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sion is reportedly less frequent in tumor cells of invasive
breast carcinomas than in situ carcinomas or non-neoplastic
breast epithelial cells [12]. In this investigation, MnSOD pro-
tein level was lower in human breast cancer cell lines with
high HER2/neu expression than in those with low HER2/
neu expression. However, the level of MnSOD seems to be
inversely related to HER2/neu expression in breast cancer cell
lines. Thus, we hypothesize that MnSOD suppresses HER2/
neu oncogene expression and alters the malignant phenotype
that is induced by the overexpression of HER2/neu in the
human breast cancer cell line. This work further clariﬁes
the role of MnSOD in the growth of breast cancer by estab-
lishing a construct with the MnSOD coding region to eluci-
date the mechanism of suppression of HER2/neu-mediated
transformation by MnSOD, and to examine its clinical
applications in human cancer gene therapy. MnSOD is
demonstrated to repress HER2/neu gene expression at the
transcriptional level in this study. Additionally, in light of
the therapeutic eﬀect of MnSOD on HER2/neu-overexpress-
ing breast cancer cells, the hypothesis that the expression of
MnSOD and then down-regulation of HER2/neu in HER2/
neu-overexpressing cells suppresses the transformation pheno-
type and metastatic potential is tested. The expression of
MnSOD in HER2/neu-overexpressing human breast cancer
MDA-MB-453 cells was enforced and MnSOD was demon-
strated eﬀectively to repress the HER2/neu gene functions –
not only reducing soft-agarose colony-forming ability, but
also inhibiting the metastasis-associated properties of
HER2/neu-overexpressing human breast cancer cells. These
results reveal that MnSOD may suppress tumors and may
have therapeutic potential against HER2/neu-induced breast
cancer cell growth.2. Materials and methods
2.1. Plasmids and bacterial strains
The pNeu-lit plasmid, in which a DNA segment that contains the
human HER2/neu promoter was fused with a luciferase reporter gene,
was kindly provided by Dr. Hung MC (University of Texas M. D.
Anderson Cancer Center, Houston, Texas). The pNeuEcoRVLuc plas-
mid, a mouse neu promoter that is fused with the luciferase gene, was
constructed and used in luciferase assay. pCMVb, a plasmid that
expresses the b-galactosidase, was used to measure transfection
eﬃciency. Plasmid pcDNA3 (Invitrogen) was an expression vector that
contained the cytomegalovirus (CMV) promoter and the neomycin-
selection marker. Plasmid pcDNA3-Hu-MnSOD expresses high levels
of human MnSOD. pMalate-Luc (malic enzyme promoter fused with
the luciferase reporter) was kindly provided by Dr. Chou WY
(National Defense Medical Center, Taipei, Taiwan). All plasmids were
ampliﬁed in Escherichia coliDH5a and puriﬁed using a QIAGEN plas-
mid Maxipreps Kit.2.2. Cell lines, culture and transfection
NIH3T3 and all the breast cancer cell lines were donated by Dr.
Hung MC (University of Texas M. D. Anderson Cancer Center, Hous-
ton, Texas). They were grown in a 1:1 mixture of Dulbecco’s modiﬁed
Eagle’s medium (DMEM)/F12 medium that was supplemented with
10% fetal bovine serum (FBS) (Invitrogen). The human MnSOD,
strongly expressing stable transfectants 453-MnSOD-3, -8, -10, -12
and -pool, were established and selected in the presence of 600 lg/ml
of G418 (Geneticin; Invitrogen) based on the transfection experiment
in which Lipofectamin plus reagent (Invitrogen) was used. Stable lines
were cultured under the same conditions as the parental line but with
added G418 (500 lg/ml) selection reagent.2.3. Luciferase reporter gene activity assay and b-galactosidase assay
NIH3T3 cells were the recipient cells for all DNA constructs in all
transient transfection experiments. The liposome-mediated gene trans-
fer technique was adopted for transient transfection (Lipofectamin
plus reagent). NIH3T3 cells were plated onto 60 mm-dishes in
DMEM/F12 medium that contained 10% FBS with 6 · 104 cells per
dish. After overnight, the cells were grown to 50–60% conﬂuence;
the medium was replaced by DMEM/F12 serum free medium, and
the cells were transfected with the pNeu-lit plasmid, pNeuEcoRVLuc,
pMalate-Luc, pcDNA3-Hu-MnSOD or pcDNA3. The total amount of
plasmid DNA was maintained at 4.5 lg per dish for cell transfection.
The plasmid pCMVb was included in all transfections as a reference
control to determine the cell transfection eﬃciency. These standard
luciferase activity assays were performed following the manufacturer’s
protocol for the Luciferase Reporter Assay System (Promega).
Extract (10–20 ll) was used to measure b-galactosidase activities, as
described in Chuang et al. [14]. Each experiment was performed at
least in triplicate.
2.4. MnSOD activity assay
MnSOD protein was visualized using native polyacrylamide gel elec-
trophoresis (PAGE), and the standard MnSOD activity assays were
performed using the nitroblue tetrazolium (NBT) reducing method
that was described by Spitz and Oberley with a slight modiﬁcation
[15]. Brieﬂy, 60 lg of the cellular protein from the parental MDA-
MB-453 line, the control pcDNA3 vector stable line or the MnSOD
cDNA stable lines were subjected to native gel electrophoresis using
a 4–20% Tris–glycine PAGE (NOVEX). Following electrophoresis,
the gel was rinsed in 3.75 mg/ml NBT solution for 15 min in the dark.
It was then rinsed once in distilled water and then soaked in 0.13 mg/
ml Vitamin B2 and 28 mM N,N,N 0,N 0-tetramethylethylenediamine
(TEMED) for 15 min. Finally, the gel was washed again in distilled
water and exposed to bright light until the gel turned blue.
2.5. Western blot analysis
Cells were harvested and washed in phosphate-buﬀered saline (PBS),
and cell pellets were extracted using lysis buﬀer (HEPES buﬀer, pH 7.0
[20 mM HEPES, 2 mM MgCl2, 10 mM KCl, 0.5% NP-40], 0.5 M
NaCl, protease inhibitor cocktail (Roche)). The protein concentration
of the extracts was determined against a standardized control using a
Bio-Rad Protein Assay Kit (Bio-Rad Laboratories, Hercules, CA).
Western blot analysis was conducted as described in [16]. The primary
antibodies were obtained as follows. Anti-neu monoclonal antibody
(Ab-3) and anti-human MnSOD polyclonal antibody were purchased
from Calbiochem, and anti-b-actin monoclonal antibody was pur-
chased from Chemicon. The secondary antibodies, which were horse-
radish peroxidase (HRP)-linked goat anti-mouse IgG and goat anti-
rabbit IgG, were purchased from Amersham.
2.6. Anchorage-independence assay
Soft agarose colony formation assay was carried out as described in
[16]. Colonies greater than 50 lm in diameter were counted for each
dish. Each assay was performed in triplicate.
2.7. Cell motility assay
The chemotaxis assay was performed using a transwell unit with an
8 lm pore-size polycarbonate ﬁlter in a 24-well cluster plate (Costar),
by the method described by Chuang et al. with a slight modiﬁcation
[16]. The conditioned medium was prepared from cells cultured in
DMEM/F12/0.1% BSA without serum for three days. After harvesting
by trypsinization, the cells were then suspended in DMEM/F12 that
contained 10% FBS to inactivate the enzyme, and then centrifuged
and resuspended in DMEM/F12 serum-free medium. Cells (5 · 104
per 0.1 ml of DMEM/F12 medium) were placed in the upper compart-
ment of the transwell unit and each lower compartment of the trans-
well contained 600 ll conditioned medium or serum-free medium
alone (as negative control). The cells were then incubated for 6 h at
37 C. After incubation, ﬁlters were ﬁxed with 3% glutaraldehyde in
PBS for 30 min and then stained with 10% Giemsa for 1 h. After wash-
ing with PBS, the cells on the upper surface of the ﬁlter were removed
by wiping with a cotton swab. Chemotactic activity was measured by
counting under a Nikon microscope (Coolpix 990) at 200· magniﬁca-
tion the number of cells that had migrated to the lower side of the
ﬁlter.
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Kendall’s tau-b correlation and linear regression analysis were used
to analyze correlations between the relatively expressed protein levels
of HuMnSOD and p185HER2/neu. SPSS software v.10.0 (SPSS UK
Ltd, Woking, UK) was used for the analysis. P < 0.05 (2-tailed) was
considered to be signiﬁcant.0
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Fig. 2. Transcriptional and dose-dependant repression of HER2/neu
by MnSOD. Increasing amounts (1 and 2 lg) of pcDNA3-MnSOD
construct, which contains the full-length cDNA of human MnSOD,
was co-transfected into NIH3T3 cells with a constant amount (2 lg) of
mouse neu (pNeuEcoRVLuc), human HER2/neu (pNeu-lit) promoter3. Results
3.1. Protein expression levels of p185HER2/neu and MnSOD in
breast cancer cell lines
HER2/neu up-regulations are associated with numerous
human cancers, including in approximately 30% of breast
cancer patients [5]. The low level of MnSOD in many tumor
cells has been documented [17]. Protein and mRNA expression
levels of MnSOD were lower in neoplastic epithelial cells of
invasive breast carcinomas than in preinvasive or non-neoplas-
tic breast epithelia [12]. Comparison of the levels of MnSOD
and p185HER2/neu in several breast cancer cell lines was per-
formed to clarify the roles of, and relation between, MnSOD
and HER2/neu in breast cancer cells. As presented in Fig. 1,
the protein level of MnSOD was inversely correlated withp185HER2/neu
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Fig. 1. Diﬀerential expression of p185HER2/neu and MnSOD proteins
in various human breast cancer cell lines. (A) Western blot analysis of
p185HER2/neu and MnSOD in the breast cancer cell lines. (B) A linear
regression curve was performed by photoshop-based protein quanti-
ﬁcation with normalized MnSOD in the ordinate and normalized
p185HER2/neu in the abscissa. A moderately inverse correlation was
present by slope = 0.164, R2 = 0.161.
constructs, or control pMalate-Luc constructs. The luciferase control
transfection activity of each promoter driven plasmid was set to 100%.
The total amount of transfected DNA was held constant by adding a
suitable amount of carrier pcDNA3. The relative luciferase activities
were the means of three independent transfections. The statistical
signiﬁcance of the diﬀerence between control and treated groups was
determined using a paired t-test. Each value in the bar graph represents
a mean value ± S.D. for three repeat samples. Signiﬁcant diﬀerence:
*P < 0.01; **P < 0.001.p185HER2/neu in breast cancer cells (Kendall’s tau-b coeﬃ-
cient = 0.571, P < 0.05). The negative association between
MnSOD and p185HER2/neu was also detected by linear regres-
sion analysis (slope = 0.164, R2 = 0.161).3.2. Transcriptional repression of HER2/neu promoter by
MnSOD is concentration-dependent
The pNeuEcoRVLuc and pNeu-lit plasmids, in which a seg-
ment contains mouse neu and human HER2/neu promoter,
respectively, were utilized in the luciferase assay. NIH3T3
was the recipient, and increasing amounts of pcDNA3-Hu-
MnSOD (human MnSOD-expressing plasmid) were co-trans-
fected with pNeuEcoRVLuc or pNeu-lit, signiﬁcantly reducing
luciferase activity. However, co-transfection with control
pMalate-Luc, MnSOD did not aﬀect luciferase activity. The
inhibition of the promoter activity of the mouse neu or human
HER2/neu depended on pcDNA3-Hu-MnSOD concentration,
with over 50% or around 40% repression, respectively,
observed at a pcDNA3-Hu-MnSOD/pNeuEcoRVLuc or
pNeu-lit ratio of 1:1 (Fig. 2). pcDNA3-Hu-MnSOD speciﬁ-
cally repressed the mouse neu and human HER2/neu promoter
without aﬀecting other promoters such as the malic enzyme
promoter.3.3. Inhibited expression of HER2/neu-encoded p185HER2/neu
in human MnSOD-overexpressing breast cancer cells
pcDNA3-Hu-MnSOD was transfected into the recipient
human HER2/neu-overexpressing breast cancer cells,
MDA-MB-453, to generate the MnSOD-overexpressing stable
4446 T.-C. Chuang et al. / FEBS Letters 581 (2007) 4443–4449transfectants, and thus elucidate the in vivo eﬀect of MnSOD
on HER2/neu gene expression. The human MnSOD-over-
expressing stable transfectants, 453-MnSOD-3, -8, -10, -12
and -pool (stable line pool from several independent
MnSOD-expressing stable transfectants), and the control
MDA-MB-453-vector pool (stable line pool from several dif-
ferent independent pcDNA3 vector only transfectants) were
established and used for further study. SOD activity assay
was performed to ensure that the exogenous MnSOD gene
was integrated into the genome of the transfectants and ex-
pressed in the MDA-MB-453 cells. Fig. 3A presents the results
of SOD activity analysis for the parental, control line and ﬁve
representative stable transfectants, 453-MnSOD-3, -8, -10, -12
and -pool. As expected, the parental and control cells exhibited
lower MnSOD activity, while the ﬁve MnSOD transfectants
had higher MnSOD activity. All the lines had equal Cu-
ZnSOD activity, which could be used as the internal control.
Western blotting analysis of the p185HER2/neu was performed
to examine whether the expression of MnSOD in 453-MnSOD
stable transfectants could inhibit HER2/neu expression. As ex-
pected, all of the MnSOD-transfected stable lines expressedHuMnSOD
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Fig. 3. Stable expression of MnSOD in HER2/neu-overexpressing
MDA-MB-453 cells reduced p185HER2/neu level. (A) Native gel analysis
of human MnSOD activity on parental and pcDNA3-MnSOD-
transfected MDA-MB-453 cells. Lane 1, parental MDA-MB-453 line.
Lane 2-5, 453-MnSOD-3, -8, -10 and -12 transfectants that were
generated by transfection of the pcDNA3-MnSOD plasmid that
contained full-length human MnSOD cDNA and the neomycin-
resistance selection marker gene into MDA-MB-453 cells. Lane 6,
control 453-vector pool was established by transfecting the pcDNA3
vector into MDA-MB-453 cells. Lane 7, 453-MnSOD-pool was pooled
together all of the pcDNA3-MnSOD plasmid-transfected MDA-MB-
453 cells. (B)Western blot analysis ofHER-2/neu-encoded p185HER2/neu
protein of parental, MDA-MB-453 (lane 1), pcDNA3 vector-transfec-
ted control pool line (lane 2), pcDNA3-MnSOD-transfected MDA-
MB-453 cell lines, 453-MnSOD-3, 8, 10, 12 (lanes 4–7) and pool lines
(lane 3).more MnSOD protein than the parental and control lines.
Surprisingly, however, the p185HER2/neu level was dramatically
reduced only in 453-MnSOD-3, -12 and -pool, but not in 453-
MnSOD-8 or -10 (Fig. 3B). A comparison with Western
blotting and SOD activity analysis in Fig. 3 indicates that
453-MnSOD-8 and -10 overexpress MnSOD, but exhibited
signiﬁcantly lower MnSOD enzyme activity. The data in
Fig. 3 reveal that enforced highly expression of MnSOD pro-
tein in HER2/neu-overexpressing breast cancer cells does not
suﬃce to repress HER2/neu expression while high MnSOD
enzyme activity expression does.
3.4. Expression of MnSOD inhibits the anchorage-independent
growth of HER2/neu-overexpressing human breast cancer
cells
Anchorage-independent growth of cells in semi-solid aga-
rose is an indicator of the transforming capacity of trans-
formed cells. The parental MDA-MB-453 cells, the control
MDA-MB-453-vector pool, and the ﬁve MnSOD-transfected
lines, 453-MnSOD-3, -8, -10, -12 and -pool, were assayed to
determine their ability to grow in soft agarose and thus eluci-
dated the eﬀect of human MnSOD expression in the HER2/
neu-overexpressing MDA-MB-453 breast cancer cells on
anchorage-independent growth. The results indicated that the
overexpression of MnSOD signiﬁcantly reduced colony forma-
tion only in such highly expressing MnSOD enzyme activity
cell lines as 453-MnSOD-3, -12 and -pool (Figs. 3 and 4),
but not in MnSOD lines with lower activity expression, 453-
MnSOD-8 and -10. These data suggest that the strong expres-
sion of MnSOD enzyme activity in the HER2/neu-overexpress-M
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Fig. 4. Soft-agarose assay of MDA-MB-453 cell lines transfected with
or without MnSOD. Brieﬂy, the four 453-MnSOD lines, their parental
MDA-MB-453 and control 453-vector-pool cells (5 · 103 cells/well)
were plated in 24-well plates in culture medium of 0.35% agarose
(GIBCO-BRL) on a 0.7% agarose layer. The cells were then incubated
at 37 C for four weeks, after which the plates were stained with
p-iodonitrotetrazolium violet (1 mg/ml) for 6 h at 37 C. Colonies that
had diameters of larger than 50 lm were counted for each dish.
Triplicate experiments were performed for each cell line. Error bars
represented the S.D. of no. of colonies/well.
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growth capacity of tumor cells.
3.5. Abrogation of metastatic properties of HER2/
neu-transformed breast cancer cells by enforced expression
of MnSOD
Tumor metastasis proceeds via a series of steps, including
vessel formation, cell attachment, invasion and cell prolifera-
tion. The metastatic phenotype involves many cellular events
and tumor cell migration may be an important indicator of
such events. HER2/neu-overexpression reportedly increases
metastasis and angiogenesis and reduces survival, particularly
of breast tumor patients [18]. The migration abilities of human
MnSOD-expressing cells and parental and control cells
towards a chemoattractant (cell-conditioned media) were mea-
sured and compared to determine whether the overexpression
of human MnSOD in MDA-MB-453 cells can inhibit the che-
motaxis of the HER2/neu-transformed breast cancer cells. As
presented in Fig. 5, all ﬁve MnSOD-transfected lines (453-
MnSOD-3, -8, -10, -12 and -pool) exhibited low chemotactic
activity, while the parental and vector pool control lines had
a higher migration rate. These results reveal that the over-
expression of human MnSOD in HER2/neu-transformed cells
can inhibit chemotaxis in HER2/neu-overexpressing breast
cancer cells.MDA-MB-453 Negative control
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Fig. 5. Inhibition of motility of HER2/neu-transformed MDA-MB-
453 cells by MnSOD. The cell motility assay was conducted as
described in Section 2. (A) The lower surface of the ﬁlter from the
transwell unit at the end of the chemotaxis assay. (B) Migrated cells
were counted in two random ﬁelds (200· magniﬁcation) and the values
are presented as means ± S.D. of three determinations. The data are
reported as percent of parental MDA-MB-453 control.4. Discussion
An increasing number of reports on the roles of MnSOD in
malignant tumors have yielded conﬂicting results. For in-
stance, high MnSOD protein levels have been found in various
malignancies, including glioblastoma, pleural mesothelioma
and gastric cancer [19–22]. However, other studies have pre-
sented the following contradictory ﬁndings. Low levels of
MnSOD have been observed in invasive breast carcinomas
more frequently than in in situ carcinomas/non-neoplastic epi-
thelia [12]. Prostatic adenocarcinomas were immunostained
with less MnSOD intensity than benign/hyperplastic glands
[23]. Immunohistochemistry staining indicated that the
MnSOD intensity is lower in human pancreatic ductal carci-
noma than in normal specimens [24]. Additionally, the overex-
pression of MnSOD cDNA inhibits the transformation
phenotype in many tumor cells [10]. Therefore, the MnSOD
gene is considered to be a tumor suppressor gene. Although
MnSOD could be used as a tumor suppressor, the molecular
feature of MnSOD in HER2/neu-transformed breast cancer
cells remains unknown. Our results indicate that HER2/neu-
overexpressing breast cancer cell lines such as MDA-MB-453
and BT-474 exhibit a low MnSOD expression, when compared
with those of low HER2/neu-expressing cell lines such as
MDA-MB-468 and MDA-MB-435 (Fig. 1). These data suggest
that HER2/neu gene expression may be repressed by MnSOD.
Furthermore, this work demonstrates that the MnSOD gene
product can repress HER2/neu gene expression at the tran-
scriptional level by targeting the promoter of both mouse
neu and human HER2 genes (Fig. 2). Accordingly, the reduced
p185HER2/neu expression in high MnSOD enzymatic activity-
expressing cell lines, MDA-MB-453-MnSOD-3, -12 and -pool,
is probably caused by the transcriptional repression of the
overexpressed HER2/neu gene (Fig. 3B). In contrast, the other
MnSOD-transfected stable clones, 453-MnSOD-8 and -10,
with enforced expression of a high level of MnSOD protein
but with low enzymatic activity, cannot suppress the HER2/
neu gene expression in HER2/neu-overexpressing MDA-MB-
453 cells (Fig. 3). A recent study had also demonstrated that
the tumor-suppressive eﬀect of MnSOD protein is caused
mainly by its enzymatic activity [25]. Therefore, the high enzy-
matic activity of MnSOD is determined perhaps to be neces-
sary in suppressing HER2/neu gene expression.
Not only does the enzymatic function of MnSOD eﬀectively
represses HER2/neu gene expression in human MDA-MB-453
breast cancer cells, but also the enzymatic function of MnSOD
is demonstrated to suppress the transformation properties by
down-regulating the endogeneous p185HER2/neu in vitro
(Fig. 4). Although transformation and metastasis are related
phenomena, they are also separable. It is suggested that they
are regulated by various molecular mechanisms [26]. In this
work, chemotaxis assay is performed to demonstrate that the
MnSOD can suppress the metastatic potential in HER2/neu-
transformed cells (Fig. 5). Our results elucidate that MnSOD
does block the proliferation of HER2/neu-overexpressing
breast cancer cells in culture. These results are in agreement
with previous reports showing that MnSOD inhibits breast
cancer cell phenotypes in vitro and in vivo [9].
ROS is known for playing critical role in cell death, carcino-
genesis or invasiveness [27]. The net intracellular level of ROS
is the result of their production and the ability of antioxidants
to remove them. Overexpression of MnSOD may lead to
4448 T.-C. Chuang et al. / FEBS Letters 581 (2007) 4443–4449changes in the superoxide anion ðO2 Þ/hydrogen peroxide
(H2O2) balance, causing changes in the redox state that aﬀects
signal transduction pathways modulating cell proliferation
[28]. MnSOD can increase the dismutation rate of O2 to
H2O2 and inhibit cancer cell growth in vitro and in vivo [9].
Therefore, it has been suggested that the MnSOD is a tumor
suppressor and the mechanism of MnSOD overexpression
may be due to, at least in part, increased H2O2 levels [9,29,30].
On the other hand, basic and clinical studies have reported a
correlation between high-MnSOD level and invasiveness of
breast cancer [31,32]. Recently, it has been suggested that
up-regulation of MnSOD is associated with low expression
of catalase and glutathione peroxidase in some estrogen-inde-
pendent cancer cells, e.g. MDA-MB-231 and SKBR-3. A high
level of MnSOD coupled to low level of catalase and glutathi-
one peroxidase, major H2O2-detoxifying enzymes, gives rise to
an overproduction of H2O2 which may regulate the tumor
growth and invasive properties in estrogen-independent breast
cancer cells [31].
Until now, mechanism for MnSOD-mediated inhibition of
breast tumor cell phenotype is not yet fully deﬁned. In this
study, we demonstrate for the ﬁrst time that the MnSOD
expression is lower in HER2/neu-overexpressing breast cancer
cells than in HER2/neu low expression cells. Furthermore, we
have shown that delivery of MnSOD into HER2/neu-over-
expressing breast cancer cells may suppress p185HER2/neu level
and HER2/neu-mediated transforming capacity. This ﬁnding
is consistent with MnSOD being a tumor suppressor gene in
human breast cancer. Unlike the previous result [31], HER2/
neu-overexpressing breast cancer cell MDA-MB-453, which
is estrogen-independent, expresses low level of MnSOD.
Therefore, the molecular mechanism(s) by which HER2/neu-
overexpressing breast cancer cells, e.g. MDA-MB-453, down-
regulate MnSOD expression and the factors inﬂuencing
MnSOD expression, have not yet been elucidated and needed
to be further deﬁned. Moreover, evolutionarily, whether major
H2O2-detoxifying enzymes such as catalase and/or glutathione
peroxidase are involved in the pathway(s) of inhibition of
HER2/neu gene expression by MnSOD in MDA-MB-453
human breast cancer cells is of interest.
Since maspin, a tumor suppressor which can inhibit breast
cancer cell invasion and metastasis, can be up-regulated by
MnSOD in human breast and prostate cancer cells [33], the
results of this study may raise a question as to whether the sup-
pression of the metastatic ability of HER2/neu-overexpressing
breast cancer cells by MnSOD depends on the repression of
HER2/neu oncogene expression. To clarify this issue,
maspin-targeted RNA interference (RNAi) may be used to
suppress the expression of the maspin gene in the MnSOD-
expressing stable transfectants such as 453-MnSOD-3.
Secondly, HER2/neu cDNA may be re-transfected into the
453-MnSOD-3 cells to restore the p185HER2/neu level. Compar-
ison of the metastasis-associated properties between these cells
and their parental lines should then reveal which of the possi-
ble molecular mechanisms is involved in the repression of
metastasis by MnSOD in breast cancer cells that are trans-
formed by HER2/neu ampliﬁcation and/or overexpression.
Finally, Li et al. demonstrated that MnSOD in human
breast cancer cells inhibits AP-1 and NF-jB, two transcription
factors that are related to tumor growth [34]. A computer
search revealed that both AP-1 and NF-jB binding sequence
are located on the human HER2/neu promoter region. Usingluciferase reporter assay, our results indicated that AP-1, but
not NF-jB, may participate in the suppression of HER2/neu
gene expression by MnSOD (data not shown). Taken together,
we postulate that down-regulation of p185HER2/neu by MnSOD
may be mediated by inhibition of AP-1 activity, but this issue
requires further study. In summary, overexpression of
MnSOD inhibited the HER2/neu gene expression at the tran-
scriptional level and suppressed the malignant phenotype of
the HER2/neu-mediated breast cancer cell. Therefore,
MnSOD may act to suppress both transformation and metas-
tasis of HER2/neu-mediated breast cancer cells.
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